reports
H & M Hennes & Mauritz AB: 1 director
A director at H & M Hennes & Mauritz AB bought 1,700,000 shares at 166.391SEK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
- Rune Majlund Dahl
Coloplast (Buy, TP: DKK1050.00) - Awaiting an acceleration in H2e
We forecast Q2 organic revenue growth of 7.6% YOY (in line with consensus), driven by the Chronic Care business segments, and an EBIT margin before special items of 27.6% (consensus 27.5%). We continue to expect QOQ improvements for the coming quarters. We expect the 2023/24 guidance to be unchanged for c8% organic revenue growth, and a 27–28% EBIT margin before special items. We reiterate our BUY, and have raised our target price to DKK1,050 (1,000).
- Simen Aas
Hennes & Mauritz (Buy, TP: SEK200.00) - 10% EBIT-margin target in its ...
A strong start to 2024, and spring sales with solid gross margins, have boosted confidence in H&M’s near-term 10% EBIT margin target. We like the store-refurbishment acceleration too, supporting our view of it returning to store growth in 2025e. We reiterate our BUY, but have raised our target price to SEK200 (180) on higher forecasts.
- Ana Arjona-Martinez
- Antonio Rodriguez Vicens
H&M : Good results on the back of outperformance from COGS
>Higher gross margin more than offsets in-line sales and higher opex… - H&M’s Q1 2024 results were ahead of our and consensus estimates (EBITDA 9.4% above consensus and 7.8% above our estimates) due to stronger tailwinds from COGS (5.8% lower than estimated) and despite in-line sales in the quarter (0.6% above consensus and 0.6% below our estimates). The better performance from COGS fed through to the rest of the P&L, obviously with a positive leverage effect, le...
- Aurore Tigerschiöld
- Aurore Tigerschiöld
- Simen Aas
Hennes & Mauritz (Buy, TP: SEK180.00) - Strong Q1
We consider this a positive report for H&M, including EBIT 53% above consensus, a reiterated 2024 EBIT margin target, and decent start to spring sales. We expect consensus 2024e adj. EBIT to come up by 5%+ on the back of the Q1 report, and believe a positive share price reaction is warranted.
- Ana Arjona-Martinez
- Antonio Rodriguez Vicens
- Ana Arjona-Martinez
- Antonio Rodriguez Vicens
- Ana Arjona-Martinez
- Antonio Rodriguez Vicens
H&M : Top line growth is key and necessary for an inflection point
>We are lowering our estimates after disappointing results in the last quarters, especially in Q4 2023, showing the challenges faced by the company… - We continue to think that H&M needs a significant change in its model in order not to lose market share, and that the results published over the last few quarters are testimony of the difficulty in achieving such transformation. The decline in sales in the last reported quarter, as well as the negative top line growth p...
- Jerôme Bodin
INFINEON INFINEON TECHNOLOGIES AG
EDEN EDENRED SA
JMT JERONIMO MARTINS SGPS S.A.
VIV VIVENDI SE
TEP TELEPERFORMANCE SE
HAL HAL TRUST
AMP AMPLIFON S.P.A.
01913 PRADA S.P.A.
AENA AENA SME SA
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
TIT TELECOM ITALIA S.P.A.
IBE IBERDROLA SA
COLO B COLOPLAST A/S CLASS B
ASML ASML HOLDING NV
HFG HELLOFRESH SE
- Jerôme Bodin
INFINEON INFINEON TECHNOLOGIES AG
EDEN EDENRED SA
JMT JERONIMO MARTINS SGPS S.A.
VIV VIVENDI SE
TEP TELEPERFORMANCE SE
HAL HAL TRUST
AMP AMPLIFON S.P.A.
01913 PRADA S.P.A.
AENA AENA SME SA
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
TIT TELECOM ITALIA S.P.A.
IBE IBERDROLA SA
COLO B COLOPLAST A/S CLASS B
ASML ASML HOLDING NV
HFG HELLOFRESH SE
- Oliver Metzger
Coloplast : Back on track
>Ostomy care - Strong growth in US to continue - While Coloplast is the strong global market leader with a share of c. 44% in ostomy care, the US represents a growth opportunity with a share in the high teens. We expect that the mixture ofsuccess at GPO contracts, major hospital groups as well as its approaches to increase awareness among patients and nurses directly, will lead to a marked improvement in traction over the next years. We forecast double-digit gr...
Coloplast AS: 1 director
A director at Coloplast AS sold 310 shares at 911.290DKK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.